Assessment of Decision Tool to Select Women for Gynecologic Sparing Radical Cystectomy
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Currently, the standard of care for female patients undergoing radical cystectomy includes the removal of the bladder, pelvic lymph nodes, anterior vagina, uterus, fallopian tubes and ovaries. Removal of female ancillary organs, both in pre and post-menopausal stages is associated with reduction in various quality of life metrics, including sexual health, cognitive decline and depression. Furthermore, removal of ovaries has been associated with increased cardiovascular events, metabolic acidosis, osteoporosis and bone fractures. In premenopausal women, the removal of the ovaries is associated with increased all-cause mortality. From an oncologic standpoint, multi institutional retrospective reviews have demonstrated certain pre-operative radiographic and cystoscopic risk factors that are associated with bladder cancer involvement of female reproductive organs. The absence of these unfavorable risk factors may provide an opportunity to spare women from undergoing unnecessary reproductive organ removal during RC. In doing so, this may eliminate the associated sequelae of removing these additional organs while also providing acceptable oncologic care. The investigators thus propose a decision tool to stratify women undergoing radical cystectomy as favorable and unfavorable for reproductive organ sparing radical cystectomy. This decision tool classification will be used to decide which patients will undergo reproductive organ sparing radical cystectomy versus radical cystectomy in this study.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Kobieta w wieku 18 lat lub więcej
- •Potwierdzony nowotwór pęcherza moczowego
- •Kandydatka do operacji usunięcia pęcherza
- •Możliwość wykonania rezonansu magnetycznego (MRI) miednicy
- •Badanie endoskopowe pęcherza wykonane w ostatnich 120 dniach
- •Badania obrazowe do oceny zaawansowania nowotworu w ostatnich 90 dniach
- •MRI miednicy wykonane w ciągu 90 dni przed operacją
- •Pisemna zgoda na udział w badaniu
✗ Disqualifies
- •Przerzuty nowotworu poza pęcherzem
- •Inny typ raka pęcherza niż urothelialny
- •Nie ma możliwości wykonania wymaganego MRI
- •Kobieta mogąca zajść w ciążę, która nie chce stosować antykoncepcji
- •Inny aktywny nowotwór w historii choroby
- •Mutacje genetyczne związane z naprawą DNA (BRCA1/BRCA2)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 99 Years
- Last updated (source)
- September 9, 2026
- Sex
- Female only
Therapies / drugs in trial
Locations (1)
University of Florida
Gainesville, United States
Trial contact
Nicole Davila Torres
Brittany S Lansford
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/10/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.